spin, spin, spin..... first, it was an advisory committee. second, post-Vioxx and with Merck as the sponsor? merely a safe and sane "we have celebrex, we have naproxen, we have ibuprofen, go away! lean to the left, lean to the right, Cleveland Clinic, sis boom ba!"
>> In voting 20-1 to reject Arcoxia, FDA's advisers said that for certain ailments, we have enough medicines. <<
Not true. Exactly the opposite view was expressed.... that NSAIDs are only modestly effective, and that we certainly have enough choices among that CLASS of therapeutic to exclude any new-comers which don't bear AKC papers on arrival. |
